pone.0295983.g004.tif (607.33 kB)
Network of the comparisons for the Bayesian network meta-analysis.
figure
posted on 2024-03-07, 18:40 authored by Lu Huan, Fucai Yu, Ding Cao, Hantao Zhou, Maoling Qin, Yang CaoThe size of the nodes is proportional to the number of patients (in parentheses) randomised to receive the treatment. The width of the lines is proportional to the number of trials (beside the line) comparing the connected treatments. (Gem: Gemcitabine; Cis: Cisplatin; PEXG: Gemcitabine + Cisplatin then oral capecitabine; mFOLFLRINOX: Ooxaliplatin + irinotecan + 5-fluorouracily; PG: Gemcitabine + nab-paclitaxel; PGH: Gemcitabine + nab-paclitaxel + hydroxychloroquine; FOLFLRINOX: Oxaliplatin + leucovorin + irinotecan.
History
Usage metrics
Keywords
thirteen eligible articlesmedian overall survivaleveryone &# 821758 – 0significant difference concerningmajor surgical complications65 – 12 neoadjuvant therapy increased0 %, pr0 resection ratesignificant differencemajor complicationsneoadjuvant therapyneoadjuvant treatmentadjuvant therapyhr 0xlink ">upfront surgerytreatment strategiessystematic reviewsurgery firststudy aimssix studiesseven studiessearched pubmedrelated reviewsratios risksprisma checklistpancreatic carcinomanetwork metamicroscopically completeindividual studiesimproved moshigh heterogeneityfront surgeryfour studiescochrane datebasecertain possibilityattention gradually15 %),00001 ),
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC